Company Overview and News
KUALA LUMPUR, Oct 17 — Bursa Malaysia closed higher today, tracking gains on the regional markets ahead of the mid-term review of the 11th Malaysia Plan (11MP), which will be tabled in Parliament tomorrow.
7036 BSMAF HIPEF 1818 5199 7079
KUALA LUMPUR (Oct 12): The FBM KLCI rose 0.79% in a technical rebound at the midday break today, snapping its seven-day losing streak, lifted by index heavyweights including Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd (TNB).
HLFBF MLYBY MLYNF 7036 1082 7006 5135 6033 5199 CIMDF 1155 KLKBY 1023 2445 PNADF 5347 TNABY 6888 0006 5819 AXXTF TNABF HIPEF PNAGF
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF
KUALA LUMPUR, Oct 11 — Bursa Malaysia ended in the red amid broad selling activities and in line with Asian markets as investors remained on the sidelines on heightened volatility in the global markets, said a dealer.
GMALF 7036 4197 5199 GMALY 5225 4715 SMEBF Q0F BSMAF IHHHF HIPEF 1818
KUALA LUMPUR, Oct 11 — Bursa Malaysia extended its losses at the opening today in line with Wall Street’s weaker performance overnight on concerns over global growth prospects.
PBLOF 5225 5819 7036 Q0F 1295 BSMAF IHHHF HIPEF 1818 5199
KUALA LUMPUR, Oct 10 — Share prices ended sharply lower across the board on Bursa Malaysia today due to a mix of local and external factors as investors, among others, cautiously digested government plans to introduce new taxes to reduce its debt obligation.
4863 PBLOF 5819 7036 MYTEF 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR (Oct 9): The FBM KLCI pared some of its losses at the midday break today, against a backdrop of weaker regional markets.
HLFBF UPBMF 7036 1082 5010 BATS 4162 2291 7765 3794 2089 5256 9334 5199 KLKBY 5139 2445 0900 8613 6888 AXXTF 5827 HIPEF 3719
KUALA LUMPUR (Oct 9): The FBM KLCI remained in negative zone at mid-morning today, in tandem with regional markets that were also mostly in the red.
SPMXF UPBMF 7036 1163 7087 ORHLF 5168 2089 5256 9334 4006 KLKBY 2445 SPMXY 5819 HRGHY
KUALA LUMPUR (Oct 8): The FBM KLCI remained marginally in the negative zone, having pared much of its losses in the morning session today, against the backdrop of weaker regional markets.
SPMXF 7036 5681 5263 BATS 4162 1163 5256 7123 5199 SPMXY 5225 3026 3301 3867 1899 Q0F IHHHF HIPEF GEBHF
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...